Locate Bio Closes £10 Million Funding Round

By Julie A. Vetalice

Locate Bio Closes £10 Million Funding Round

Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that it has raised an oversubscribed £10 million (~USD $13.4 million) of equity investment in a funding round co-led by existing shareholder Mercia Asset Management and new investor BGF. The funding will be used to further advance Locate Bio’s proprietary pipeline of regenerative orthobiologics products towards patients, with key clinical and regulatory milestones expected to catalyse growth over the next two years.

The investment brings the total funds raised by Locate Bio to over £18 million. The company’s lead product in development is called LDGraft, and is a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease. In September 2020, Locate Bio in-licensed multiple late-stage orthobiologics assets from the Royal College of Surgeons in Ireland’s (RCSI) University of Medicine and Health Sciences. The acquisition of these products significantly accelerated Locate Bio’s ambitions of building a world-leading, diversified orthobiologics company.

Locate Bio aims to develop a suite of best-in-class technologies that address the performance limitations of existing products and enable orthopedic surgeons to improve the lives of people suffering from debilitating conditions. The company is making good progress against this objective and received two breakthrough device designations from FDA at the start of 2021 for CognitOss and Chondro3, a biomimetic graft for osteochondral lesions. CognitOss is a single-stage therapy that combines the local delivery of therapeutically appropriate levels of antibiotics from a ‘smart material’ that is designed to be responsive to the presence of infection and promote the regeneration of bone. It is designed to treat osteomyelitis, a debilitating inflammatory bone infection.

John von Benecke, CEO of Locate Bio, said, “This investment round is truly transformational for Locate Bio and I would like to thank Mercia for their continued support and collaboration and to welcome BGF. We are developing a suite of promising next-generation orthobiologics products that have the potential to disrupt the market and bring significant benefits to patients with debilitating conditions. Following our spin out from The University of Nottingham’s internationally recognised School of Pharmacy, we bring the strength of controlled drug delivery, to the principally medical device field of orthopaedics. We have continued to make good progress in our strategy of building a world leading, diversified orthobiologics business, which has resulted in this oversubscribed funding round. This financing will allow us to further develop our exciting portfolio of differentiated products as we embark on our next phase of growth.”

Source: Locate Bio

Product Labels: Bone Graft Materials/DBM, Synthetic Bone Graft, PRP/Cell-Based/Osteoinductive Materials

Tags: Funding